<DOC>
	<DOCNO>NCT00717990</DOCNO>
	<brief_summary>This study evaluate efficacy Irinotecan , Capecitabine Avastin combination patient response previous treatment 5-Fluorouracil , Leucovorin , Eloxatin Avastin .</brief_summary>
	<brief_title>Irinotecan , Capecitabine Avastin Metastatic Colorectal Cancer Salvage Treatment</brief_title>
	<detailed_description>The aim phase II study evaluate efficacy combination XELIRI/AVASTIN patient mCRC , progress first line treatment FOLFOX/AVASTIN . For AVASTIN select dose schedule trial TREE 1 2 [ 17 ] , Avastin combine capecitabine oxaliplatin three week schedule adaptation dose 7,5 mg/kg</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Histologically confirm locally advanced metastatic colorectal cancer Measurable evaluable disease accord Response Evaluation Criteria Solid Tumors ECOG performance status ≤ 2 Age 18 72 year Patients progress 1st line therapy FOLFOX/AVASTIN Adequate liver ( Bilirubin ≤ 1.5 upper normal limit , SGOT/SGPT ≤ 4 upper normal limit , ALP ≤ 2.5 upper normal limit ) renal ( Creatinine ≤ 1.5 upper normal limit ) bone marrow ( ANC ≥ 1,500/mm3 , PLT ≥100,000/mm3 ) function Patients must able understand nature study Written inform consent History serious cardiac disease ( unstable angina , congestive heart failure , uncontrolled cardiac arrhythmia ) History myocardial infarction stroke within 6 month Clinically significant peripheral vascular disease History abdominal fistula , gastrointestinal perforation intraabdominal abscess within 28 day prior Day 0 Major surgical procedure , open biopsy , significant traumatic injury within 30 day prior Day 1 Presence central nervous system brain metastasis Evidence bleed diathesis coagulopathy Blood pressure &gt; 150/100 mmHg Pregnant lactate woman Life expectancy &lt; 3 month Previous radiotherapy within last 4 week &gt; 25 % bone marrow Metastatic infiltration liver &gt; 50 % Patients chronic diarrhea ( least 3 month ) partial bowel obstruction total colectomy Active infection require antibiotic Day 1 Second primary malignancy , except nonmelanoma skin cancer situ cervical cancer Psychiatric illness social situation would preclude study compliance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>72 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Colorectal cancer</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>XELIRI</keyword>
</DOC>